Sector
PharmaceuticalsOpen
₹203.2Prev. Close
₹200.99Turnover(Lac.)
₹11,071.93Day's High
₹204.46Day's Low
₹200.9352 Week's High
₹307.952 Week's Low
₹145.25Book Value
₹55.74Face Value
₹10Mkt Cap (₹ Cr.)
26,961.14P/E
39.02EPS
5.2Divi. Yield
0.0713 Jun 2025
12:00 AM
Board Meeting
Agenda : Audited Result
11 Jun 2024
12:00 AM
AGM
Announcement Date: 11 Jun, 2024
The company stated in its filing with the bourses that its remains committed to maintain highest compliance standards.
Piramal Critical Care has reserved commercialisation rights for the EU, UK, and Norway and will look after Neoatricon in these regions.
This month, the US FDA inspected the facility and after inspection issued a Form 483 of six observations as the company has to improve compliance in this regard.
In response to growing demand of IA, capacity expansions are under way at both Dahej and Digwal facilities, with month-on-month production growth.
As part of long-term strategy PCC has seen a number of product launches during recent times which are building block towards market presence in generic injectables.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 1,322.95 | 1,193.32 | 1,185.91 | 994.7 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 5,389.12 | 4,068.47 | 3,937.21 | 3,105.92 |
Net Worth | 6,712.07 | 5,261.79 | 5,123.12 | 4,100.62 |
Minority Interest |
No Record Found
No Record Found
No Record Found
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Gross Sales | 9,151.18 | 8,171.16 | 7,081.55 | 6,559.1 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 9,151.18 | 8,171.16 | 7,081.55 | 6,559.1 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 207.74 | 234.88 | 279.44 | 334.83 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson
Nandini Piramal
Executive Director & CEO
PETER D DEYOUNG
Independent Director
Jairaj Purandare
Independent Director
S Rama Dorai
Independent Director
Peter Stevenson
Independent Director
Sridhar Gorthi
Independent Director
Vibha Paul Rishi
Executive Director & CFO
Vivek Valsaraj
Company Sec. & Compli. Officer
Tanya DCosta
Additional Director
Nathalie Leitch
Additional Director
Amit Jain
Ground Floor Piramal Ananta,
Agastya Corp.Park LBS MargKurl,
Maharashtra - 400070
Tel: 91-22-3802-3000/4000
Website: http://www.piramalpharma.com
Email: corporate.secretarial@piramal.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-...
Read More
Reports by Piramal Pharma Ltd
What is the Piramal Pharma Ltd share price today?
What is the Market Cap of Piramal Pharma Ltd?
What is the PE and PB ratio of Piramal Pharma Ltd?
What is the 52 Week High and Low of Piramal Pharma Ltd?
What is the CAGR of Piramal Pharma Ltd?
What is the shareholding pattern of Piramal Pharma Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
